Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
MJ Grant, RS Herbst, SB Goldberg - Nature reviews Clinical oncology, 2021 - nature.com
The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …
evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have …
Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review
X Zou, XY Tang, ZY Qu, ZW Sun, CF Ji, YJ Li… - International Journal of …, 2022 - Elsevier
Platelet-derived growth factors (PDGFs) and PDGF receptors (PDGFRs) are expressed in a
variety of tumors. Activation of the PDGF/PDGFR signaling pathway is associated with …
variety of tumors. Activation of the PDGF/PDGFR signaling pathway is associated with …
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a …
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
C Zhu, Y Wei, X Wei - Molecular cancer, 2019 - Springer
Molecular targeted therapy for cancer has been a research hotspot for decades. AXL is a
member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 …
member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 …
Role of VEGFs/VEGFR-1 signaling and its inhibition in modulating tumor invasion: experimental evidence in different metastatic cancer models
C Ceci, MG Atzori, PM Lacal, G Graziani - International journal of …, 2020 - mdpi.com
The vascular endothelial growth factor (VEGF) family members, VEGF-A, placenta growth
factor (PlGF), and to a lesser extent VEGF-B, play an essential role in tumor-associated …
factor (PlGF), and to a lesser extent VEGF-B, play an essential role in tumor-associated …
Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer
Cancer often develops multidrug resistance (MDR) when cancer cells become resistant to
numerous structurally and functionally different chemotherapeutic agents. MDR is …
numerous structurally and functionally different chemotherapeutic agents. MDR is …
Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies
RJ Walsh, RA Soo - Therapeutic advances in medical …, 2020 - journals.sagepub.com
The treatment landscape for patients with advanced non-small cell lung cancer has evolved
greatly with the advent of immune checkpoint inhibitors. However, many patients do not …
greatly with the advent of immune checkpoint inhibitors. However, many patients do not …
A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy
The accumulation of immune-suppressive myeloid cells is a critical determinant of
resistance to anti–programmed death-1 (PD-1) therapy in advanced clear cell renal cell …
resistance to anti–programmed death-1 (PD-1) therapy in advanced clear cell renal cell …
MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression
J Lin, A Xu, J Jin, M Zhang, J Lou, C Qian, J Zhu… - …, 2022 - Taylor & Francis
The poor progress of immunotherapy on osteosarcoma patients requires deeper delineation
of immune tolerance mechanisms in the osteosarcoma microenvironment and a new …
of immune tolerance mechanisms in the osteosarcoma microenvironment and a new …
[HTML][HTML] Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
S Peters, L Paz-Ares, RS Herbst… - … for Immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Lung cancer remains a leading cause of cancer death worldwide, with non-small-cell lung
cancer (NSCLC) accounting for the majority of cases. Immune checkpoint inhibitors (CPIs) …
cancer (NSCLC) accounting for the majority of cases. Immune checkpoint inhibitors (CPIs) …